Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at assumed coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright upped their price target on shares of Alimera Sciences from $8.00 to $9.00 and gave the company a “buy” rating in a report on Thursday.

Alimera Sciences Stock Up 7.1 %

Shares of NASDAQ:ALIM opened at $5.71 on Monday. The company’s fifty day moving average is $5.52 and its two-hundred day moving average is $5.23. Alimera Sciences has a 12-month low of $3.94 and a 12-month high of $9.79. The company has a market cap of $39.99 million, a P/E ratio of -5.65 and a beta of 1.46.

Alimera Sciences (NASDAQ:ALIMGet Rating) last posted its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. During the same quarter last year, the company earned $0.76 earnings per share. Equities research analysts anticipate that Alimera Sciences will post -2.08 earnings per share for the current year.

Hedge Funds Weigh In On Alimera Sciences

An institutional investor recently bought a new position in Alimera Sciences stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Alimera Sciences, Inc. (NASDAQ:ALIMGet Rating) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned about 3.58% of Alimera Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). 40.97% of the stock is owned by institutional investors.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Featured Articles

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.